Verona Pharma plc (VRNA)
| Market Cap | 1.23B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -54.37M |
| Shares Out | 80.44M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 241,512 |
| Open | 15.86 |
| Previous Close | 15.59 |
| Day's Range | 15.16 - 15.95 |
| 52-Week Range | 11.83 - 23.81 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 33.60 (+120.47%) |
| Earnings Date | May 7, 2024 |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing en... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VRNA stock is "Strong Buy." The 12-month stock price forecast is $33.6, which is an increase of 120.47% from the latest price.
News
Andrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr.
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m...
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quart...
Michael Austwick Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the...
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
Strengthens financial flexibility to support the Company's continued growth Strengthens financial flexibility to support the Company's continued growth
Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive ...
Verona Pharma Announces November 2023 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the...
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call...
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory disea...
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investor...
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and...
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
PDUFA Target Action Date of June 26, 2024
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 Substantial reductions in rate and ris...
Christina Ackermann Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a ...
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to supp...
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory disea...
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory disea...
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine
Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal Ensifentrine improved lung function, symptoms and qua...
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Foo...
Verona Pharma to Present at Jefferies Healthcare Conference
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the ...
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support com...
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory dise...
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory dise...